Abstract
Npt2 encodes a renal-specific, brush-border membrane Na+-phosphate (Pi) cotransporter that is expressed in the proximal tubule where the bulk of filtered Pi is reabsorbed. Mice deficient in the Npt2 gene were generated by targeted mutagenesis to define the role of Npt2 in the overall maintenance of Pi homeostasis, determine its impact on skeletal development, and clarify its relationship to autosomal disorders of renal Pi reabsorption in humans. Homozygous mutants (Npt2−/−) exhibit increased urinary Pi excretion, hypophosphatemia, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant hypercalcemia, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity. These biochemical features are typical of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a Mendelian disorder of renal Pi reabsorption. However, unlike HHRH patients, Npt2−/− mice do not have rickets or osteomalacia. At weaning, Npt2−/− mice have poorly developed trabecular bone and retarded secondary ossification, but, with increasing age, there is a dramatic reversal and eventual overcompensation of the skeletal phenotype. Our findings demonstrate that Npt2 is a major regulator of Pi homeostasis and necessary for normal skeletal development.
Inorganic phosphate (Pi) is essential for a variety of cellular processes including skeletal mineralization. Because a disturbance in Pi availability can affect the functional integrity of many organ systems, specialized tissues have evolved to maintain the extracellular Pi concentration. In mammals, the regulation of Pi homeostasis is largely determined by the kidney, with 60–70% of the filtered Pi load reclaimed in the proximal segment of the nephron (1). Transepithelial transport of Pi from the renal lumen to the blood compartment involves uptake across the brush-border membrane (BBM), translocation across the cell, and efflux across the basolateral membrane (2). Evidence suggests that Pi transport across the BBM is the rate-limiting step in the overall Pi reabsorptive process and the major site for its regulation (2, 3). Kinetics studies demonstrated that the transport is mediated by high capacity, low affinity, and low capacity, high affinity Na+–Pi cotransport systems (4).
Recently, cDNAs encoding two distinct low capacity, high affinity, renal BBM Na+–Pi cotransporters (NPT1 and NPT2) that share only 20% identity have been identified in several mammalian species by expression and homology cloning (5–13). NPT2 is expressed exclusively in the proximal convoluted tubule and is regulated by Pi intake (14) and parathyroid hormone (PTH) (15), factors known to regulate renal BBM Na+–Pi cotransport. In contrast, NPT1 is expressed throughout the proximal tubule and is not subject to regulation by dietary Pi (10).
X-chromosome-linked and autosomal disorders of renal Pi reabsorption have been described in humans (16). Both are characterized by growth retardation, rachitic and osteomalacic bone disease, and hypophosphatemia, secondary to a renal defect in Pi reabsorption (17). Although renal Npt2 gene expression is significantly reduced in the murine Hyp (18) and Gy (19) homologs of X-chromosome-linked hypophosphatemia, localization of the NPT2/Npt2 gene to human chromosome 5q35 (20, 21) and mouse chromosome 13B (22) excluded it as a candidate gene. However, it is not yet clear whether mutations in NPT2 are responsible for autosomal disorders of renal Pi wasting and mouse models for these disorders are not available.
To define the precise role of the NPT2 transporter in the overall maintenance of Pi homeostasis and to ascertain whether the phenotypic manifestations of autosomal hypophosphatemias can arise from mutations at the NPT2 locus, we have disrupted the murine Npt2 gene by homologous recombination in embryonic stem (ES) cells and introduced the mutation in the mouse germ line.
MATERIALS AND METHODS
Derivation of Mice Mutant for Npt2.
A genomic clone encoding exons 2–12 of the Npt2 gene, obtained by screening a λ DASH II mouse (129Sv strain) genomic DNA library with a rat Npt2 cDNA probe (23), was used to generate a 2.2-kb EcoRI fragment encoding exons 2–5, and a 2.0-kb EcoRI–PstI fragment containing part of intron 10 (Fig. 1a). The Npt2 fragments were cloned into the pPNT plasmid (24), respectively, 5′ and 3′ of a neomycin resistance (neor) gene (Fig. 1a). The pPNT plasmid also contained a herpes simplex virus thymidine kinase (hsv-tk) gene, permitting selection against random integration. The resulting targeting vector, pPNT-Npt2 (Fig. 1b), was CsCl purified and linearized at the unique NotI site before electroporation.
Exponentially growing D3 ES cells (4.2 × 106) were electroporated (Bio-Rad Gene Pulser at 240 V, 500 μF) with 20 μg of pPNT-Npt2 as described (25) and selected in a medium containing 350 μg/ml G418 and 0.2 μM FIAU [1-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)-5-iodouracil] for 5 days, and then for 3 more days with G418 alone. Genomic DNA was isolated from 170 doubly resistant ES cell clones, digested with EcoRI, transferred to supported nitrocellulose membranes [Optitran BA-(S)85, Schleicher & Schuell], and hybridized with probe A, located 3′ to the insertion point of the targeting vector (Fig. 1b) according to standard procedures (26). Seven positive clones were further analyzed by Southern blot analysis by using probes A, B, and C (Fig. 1b) after digestion of the DNA with three different restriction enzymes (Fig. 1c), and five clones with the predicted homologous integration were identified. Chimeric mice were generated from three different clones as described by Bradley (27). Briefly, 12–17 ES cells were injected into 3.5-day-old blastocysts obtained from naturally mated C57BL/6J females. The injected blastocysts were transferred to uteri of 2.5-day postcoitum, pseudopregnant CD1 recipients. Pups were born after 17 days and germ-line transmission of the mutation was determined by Southern blot analysis and PCR amplification of tail DNA (see below). To produce Npt2−/− mice, heterozygous offspring were intercrossed. The mice studied were of 129Sv and C57BL/6J mixed genetic background and maintained on Rodent Laboratory Chow (Ralston Purina, diet no. 5001) containing 1% calcium, 0.61% Pi, and 4.5 units of vitamin D3/g. All experiments were conducted in accordance with the guidelines of the Canadian Council on Animal Care.
Genotyping of Mice.
Mice were genotyped by Southern blot analysis and PCR. Genomic DNA was digested with EcoRI and analyzed by Southern blot hybridization using probe A (Fig. 1b). Expected sizes of fragments for the normal and disrupted alleles are 8 and 12 kb, respectively (Fig. 1d). PCR typing of tail DNA was performed by using Taq polymerase and 3 primers: sense primer 1 (5′-TGCCCAGGTTGGCACGAAGC-3′) in exon 4, antisense primer 2 (5′-AGTCCTGTCCCCTGCCTGCA-3′) in exon 6, and antisense primer 3 (5′-TGCTACTTCCATTTGTCACGTCC-3′) in the neor gene cassette (Fig. 1b). Expected sizes of amplified fragments are 1.8 kb for the normal allele (primers 1 and 2) and 1.4 kb for the disrupted allele (primers 1 and 3) (Fig. 1e).
Analysis of RNA.
Total RNA (15 μg), isolated with TRIzol Reagent (GIBCO/BRL), was size fractionated on a 1.5% agarose/formaldehyde gel and transferred to Hybond-N nylon membranes (Amersham). The blots were probed as described (28) with a full-length rat Npt2 cDNA and an 18S rRNA oligonucleotide. Filters were washed to high stringency, exposed to Kodak Biomax MR1 film at −80°C, and RNA abundance quantitated by densitometric analysis using an LKB Ultroscan Laser Densitometer under conditions where linearity was observed. For reverse transcriptase–PCR (RT-PCR), total RNA (5 μg) was reverse transcribed by using random hexamers and SuperScript reverse transcriptase (GIBCO/BRL), as recommended by the manufacturer. Primers 1 and 2 were used for detection of Npt2 sequences.
BBM Vesicle Preparation, Western Blot Analysis, and Transport Studies.
Renal BBM vesicles were prepared from kidney cortex by the MgCl2 precipitation method as described (29) and used for both Western blot analysis and transport studies. BBM proteins were separated on 10% SDS/PAGE gels according to the method of Laemmli (30), transferred to supported nitrocellulose membranes (Hybond-C extra, Amersham), and probed sequentially with a rabbit polyclonal anti-rat Npt2 antibody (gift of H. Murer) (18) and a mAb raised against the α-subunit of rat meprin (gift of P. Crine) (31). Primary antibodies were visualized by using an enhanced chemiluminescence kit (Amersham). Quantitation of the signal was achieved by densitometric analysis using an LKB Ultroscan Laser Densitometer under conditions where linearity was observed.
The uptakes of Pi (100 μM) and glucose (10 μM), each performed in quadruplicate, were measured at 6 s, 30 s, 60 s, and 90 min in medium containing either 100 mM NaCl or 100 mM KCl by the rapid filtration technique described (29).
Serum and Urine Parameters.
Serum Pi, Ca, and alkaline phosphatase (ALPase) activity and urine Pi, Ca, and creatinine were assayed on a Hitachi 917 automatic analyzer (Hitachi, Tokyo). The fractional excretion indexes FEIPi and FEICa were calculated as follows: urine Pi or Ca/(urine creatinine × serum Pi or Ca). The serum concentration of 1,25-dihydroxyvitamin D [1,25(OH)2D] was measured by using a calf thymus radioreceptor assay kit (Incstar, Stillwater, MN). The serum concentration of PTH was measured by using a rat PTH immunoradiometric assay kit (Nichols Institute, San Juan Capistrano, CA). Urine amino acids were determined on a Beckman 6300 amino acid analyzer (Beckman) and urine glucose and protein with Aimes Mulitistix (Miles).
Bone Histology.
Tibiae from 21-, 45-, 74-, 115-, and 184-day-old mice were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C for 12 h and then decalcified in 10% EDTA (pH 7.4) at 4°C for 10 days prior to dehydration with an increasing concentration of ethanol. Bones were then embedded in paraffin and sections were stained with haematoxylin/eosin. Number and length of trabeculae were determined in an area of 300 μm in length from the chondro-osseous junction to the diaphysis surrounded by cortical bone on both sides.
RESULTS
Targeted Disruption of the Npt2 Gene.
To inactivate the Npt2 gene, we constructed a targeting vector in which Npt2 genomic fragments, encoding exons 2–5 and intron 10, respectively, were cloned into the XhoI and EcoRI sites of the pPNT plasmid (24), 5′ and 3′ to the neor gene (Fig. 1a). A double cross-over event would lead to the replacement of 7.7 kb of the Npt2 gene (corresponding to amino acids 178–389 of the Npt2 protein) with the neor gene (Fig. 1b). By using Southern blot analysis, 5 of 170 doubly resistant ES cell clones were found to have undergone homologous recombination, generating a 12-kb EcoRI fragment from the targeted allele and an 8-kb fragment from the normal allele (Fig. 1c).
Germ-line transmission of the inactivated Npt2 allele resulted in mice heterozygous for the mutation. Southern blot analysis (Fig. 1d) and PCR (Fig. 1e) were used to genotype the offspring of heterozygous matings. From a total of 404 mice, 110 were wild type (27%), 200 were heterozygotes (50%), and 94 were homozygous mutants (23%), close to the expected Mendelian ratio (1:2:1), indicating the absence of prenatal homozygous lethality. However, of the 94 Npt2−/− mice genotyped, 41 (44%) died before or at weaning. This proportion was significantly higher than that observed for wild-type and heterozygous mice.
Phenotypic Features of Npt2-Deficient Mice.
Npt2−/− mice were noticeably smaller than wild-type littermates and body weight was significantly reduced at birth (1.49 ± 0.08 g, n = 8 vs. 1.89 ± 0.12 g, n = 11, P < 0.05) and remained so for at least 4 months thereafter (Fig. 2). During the first 2 weeks of life, Npt2−/− mice showed apparent muscle weakness, some lethargy, and frequently had trouble feeding, suggesting that poor nutritional status likely contributed to their premature death. Npt2−/− mice that survived weaning appeared normal thereafter, despite smaller size and lower body weight (Fig. 2). Npt2−/− mice have a lower reproductive ability than wild-type and heterozygous animals.
Blood and urine parameters of Npt2−/− mice differed significantly from those of wild-type and heterozygous littermates (Table 1). The serum Pi concentration was markedly reduced at all ages examined and, in agreement with earlier work (32), decreased with age in all three genotypes (Table 1). The urine Pi/creatinine ratio and the fractional excretion index for Pi (FEIPi) were strikingly elevated in Npt2−/− mice (Table 1). In addition, homozygous mutants exhibited an appropriate elevation in serum 1,25(OH)2D levels in response to hypophosphatemia (Table 1). At all ages examined, the serum concentration of calcium was slightly but significantly elevated in Npt2−/− mice and showed no age dependence (Table 1). The urine calcium/creatinine ratio and FEICa were greatly increased and the serum PTH concentration was appropriately decreased in Npt2−/− mice (Table 1). There was no evidence for amino aciduria, glycosuria, or proteinuria in Npt2−/− mice (data not shown), indicating that a generalized tubulopathy was not responsible for the renal Pi leak in homozygous mutant mice.
Table 1.
Age, months | Npt2+/+(n) | Npt2+/−(n) | Npt2−/−(n) | |
---|---|---|---|---|
Serum Pi, mM | 1 | 2.87 ± 0.07 (20) | 2.78 ± 0.06 (37) | 1.86 ± 0.08 (11)** |
2 | 2.35 ± 0.09 (6) | 2.41 ± 0.06 (6) | 1.79 ± 0.06 (7)** | |
3 | 2.10 ± 0.08 (9) | 2.30 ± 0.08 (9) | 1.77 ± 0.10 (7)* | |
4 | 2.10 ± 0.07 (6) | 2.08 ± 0.18 (6) | 1.65 ± 0.14 (4)* | |
5 | 1.94 ± 0.14 (6) | 1.97 ± 0.10 (7) | 1.58 ± 0.03 (4)* | |
6 | 1.85 ± 0.09 (5) | 2.02 ± 0.08 (7) | ND | |
7 | 1.79 ± 0.08 (4) | 1.88 ± 0.13 (5) | ND | |
Urine Pi/creatinine† | 9.83 ± 1.15 (26) | 16.62 ± 1.61 (37)* | 24.98 ± 2.02 (21)** | |
FEIPi‡ | 4.22 ± 0.63 (16) | 6.79 ± 0.75 (28)* | 13.24 ± 1.08 (9)** | |
Serum total Ca2+, mM | 1 | 2.25 ± 0.03 (20) | 2.21 ± 0.03 (34) | 2.64 ± 0.05 (12)** |
2 | 2.19 ± 0.04 (5) | 2.21 ± 0.03 (6) | 2.36 ± 0.05 (7)* | |
3 | 2.20 ± 0.05 (9) | 2.13 ± 0.06 (8) | 2.41 ± 0.08 (10)* | |
4 | 2.26 ± 0.03 (6) | 2.24 ± 0.05 (6) | 2.42 ± 0.04 (3)* | |
5 | 2.00 ± 0.12 (5) | 2.13 ± 0.05 (7) | 2.48 ± 0.02 (3)* | |
6 | 2.22 ± 0.09 (3) | 2.32 ± 0.09 (8) | ND | |
7 | 2.40 ± 0.06 (2) | 2.23 ± 0.04 (3) | ND | |
Urine Ca2+/creatinine† | 0.81 ± 0.07 (23) | 1.00 ± 0.12 (36) | 7.90 ± 1.07 (20)** | |
FEICa+‡ | 0.36 ± 0.04 (15) | 0.52 ± 0.07 (27) | 3.43 ± 0.46 (10)** | |
Serum 1,25(OH)2D,§ pg/ml | 36.3 ± 9.5 (3) | 73.0 ± 7.2 (3)* | 107.3 ± 11.1 (3)** | |
Serum PTH,¶ pg/ml | 18.83 ± 1.14 (3) | 19.79 ± 2.31 (3) | 6.98 ± 0.60 (3)** | |
Serum ALPase, units/liter | 1 | 425 ± 35 (19) | 459 ± 22 (32) | 869 ± 165 (12)** |
2 | 179 ± 28 (4) | 208 ± 19 (6) | 361 ± 17 (7)** | |
3 | 126 ± 9 (9) | 99 ± 7 (9) | 175 ± 15 (8)* | |
4 | 91 ± 6 (6) | 82 ± 8 (6) | 105 ± 10 (4) | |
5 | 71 ± 14 (5) | 63 ± 3 (7) | 98 ± 7 (3) | |
6 | 92 ± 5 (3) | 64 ± 10 (7) | ND | |
7 | 84 ± 0 (2) | 61 ± 12 (3) | ND |
Results are means ± SEM (n, number of mice analyzed). ND, test not performed. ∗, P = 0.05–0.01 for t test comparing mutant mice to Npt2+/+ mice. ∗∗, P < 0.01 for t test comparing mutant mice to Npt2+/+ mice.
Assays were done on urine collected from 1- to 3-month-old animals.
FEI indicates the ratio between urine Pi or Ca (mM)/{urine creatinine (mM) × serum Pi or Ca (mM)} (1-month-old animals).
1,25(OH)2D assays were done in duplicate on three serum pools from six mice each (1- to 3-month-old animals).
PTH assays were done in duplicate on three serum pools from two or three mice each (2- to 3-month-old animals).
Serum ALPase activity decreased with age in young normal and mutant mice but, by 4 months of age, was no longer age dependent (Table 1). However, serum ALPase activity was significantly higher in young Npt2−/− mice than that in age-matched wild-type and heterozygous mice and, by 4 months of age, was comparable in all three genotypes (Table 1).
Heterozygous mice were indistinguishable from their wild-type littermates with respect to size, body weight (Fig. 2), behavior, and reproductive ability. However, a few differences in their blood and urine biochemical profiles were apparent (Table 1). Although Npt2+/− mice had a normal serum Pi concentration, their urine Pi/creatinine ratio and FEIPi were significantly elevated compared with wild-type mice (Table 1). Npt2+/− mice also exhibited elevated serum 1,25(OH)2D levels (Table 1).
Npt2 Gene Expression.
Northern blot analysis of total RNA isolated from bone, kidney, liver, and lung of animals from the three genotypes revealed the presence of a 2.6-kb transcript in the kidney of wild-type and heterozygous mice but not in the kidney of homozygous mutants (Fig. 3a). Quantitation of the 2.6-kb transcript, relative to 18S rRNA, indicated that Npt2+/− mice had ≈50% of the wild-type Npt2 mRNA, consistent with the presence of only one functional Npt2 allele. RT-PCR with Npt2 primers also confirmed the absence of detectable renal Npt2 mRNA in Npt2−/− mice (Fig. 3b). In agreement with previous work (8), Npt2 transcripts were only detectable in the kidney (Fig. 3 a and b).
Western blot analysis of renal BBM proteins demonstrated the presence of an 86-kDa protein in Npt2+/+ and Npt2+/− mice that was not detectable in homozygous mutants (Fig. 3c). Despite the reduction in Npt2 mRNA expression in Npt2+/−mice, the abundance of Npt2 protein, relative to that of meprin, was as prominent as in wild-type animals (Fig. 3c), consistent with the well-documented adaptive up-regulation of Npt2 protein in states of hypophosphatemia (14, 19, 33).
To assess the effect of the disrupted Npt2 allele on functional activity, we examined the time course of Na+–Pi cotransport in renal BBM vesicles isolated from Npt2+/+, Npt2+/−, and Npt2−/− mice. The Na+-dependent component of Pi uptake at 6, 30, and 60 s is similar in BBM vesicles from wild-type and heterozygous mice but is reduced by 79%, 71%, and 69%, respectively, in mutant homozygotes (Fig. 3d). However, at equilibrium (90 min), when the Na+-gradient has dissipated, Pi uptake is comparable in all three groups of mice (Fig. 3d). Moreover, the Na+-independent component of Pi uptake (Fig. 3d) and Na+-dependent and independent glucose uptake, measured in parallel (data not shown), were also similar in all three genotypes.
Skeletal Phenotype of Npt2-Deficient Mice.
Histological analysis of tibial sections from 21-day-old animals revealed that Npt2−/− mice have poorly developed metaphyseal trabeculae and retarded secondary ossification in the epiphysis when compared with wild-type littermates (Fig. 4a). In Npt2+/− mice, these features are intermediate between wild-type and homozygous littermates (Fig. 4a). At 21 days of age, both the length (+/+, 163 ± 31; +/−, 127 ± 33; −/−, 98 ± 15; mean ± SD, μm; +/− vs. +/+, P < 0.01; −/− vs. +/+, P < 0.005) and number (+/+, 41 ± 3; +/−, 37 ± 5; −/−, 21 ± 3; mean ± SD; +/− vs. +/+, not significant; −/− vs. +/+, P < 0.005) of metaphyseal trabeculae are decreased in homozygous mutants and intermediate in heterozygotes when compared with wild-type littermates. In addition, differences in osteoclast (tartrate-resistant acid phosphatase positive cells) distribution and osteopontin-immunopositive bone surfaces as well as a decrease in osteoclast number are apparent in tibiae of 21-day-old Npt2−/− mice and wild-type littermates, suggestive of a defect in bone remodeling in the homozygous mutants (data not shown).
In contrast, tibial sections from 45-day-old mice failed to demonstrate the genotype differences evident at 21 days of age (data not shown). At 115 days of age, however, the number of metaphyseal trabeculae in Npt2−/− mice is significantly greater than that of Npt2+/+ littermates (+/+, 16 ± 3; +/−, 21 ± 3; −/−, 25 ± 3; mean ± SD; +/− vs. +/+, P < 0.05; −/− vs. +/+, P < 0.005) and the area of epiphyseal bone marrow in the homozygous mutants is partially occupied with calcified bone (Fig. 4b). Similar findings are observed at 74 and 184 days of age (data not shown).
DISCUSSION
We demonstrate that Npt2-deficient mice exhibit increased urinary Pi excretion, hypophosphatemia, and an appropriate adaptive increase in the circulating concentration of 1,25-(OH)2D. Additional biochemical findings in Npt2−/− mice include hypercalcemia, hypercalciuria, decreased serum PTH levels, and elevated serum ALPase activity. These biochemical features are typical of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a Mendelian disorder of renal Pi reabsorption (17). In contrast to patients with HHRH, Npt2−/− mice do not exhibit rickets and osteomalacia. Rather, the mutant homozygotes have a complex bone phenotype with retarded secondary ossification at weaning followed by a reversal and eventual overcompensation of the early bone phenotype with increasing age.
The phenotypic features that characterize Npt2−/− mouse are likely the direct consequence of impaired renal Pi reabsorption, secondary to the loss of Npt2 function in the kidney. This conclusion is based on the report that Npt2 is expressed exclusively in the kidney (8) and is confirmed by the present findings. We were unable to detect Npt2 mRNA expression in bone, liver, and lung of normal mice by either Northern blot analysis or RT-PCR. In addition, by using a RNase protection assay, we did not detect Npt2 transcripts in mouse intestine (data not shown), a tissue that has considerable morphological and functional similarity to the renal epithelium. Accordingly, the molecular entities that mediate Na+–Pi cotransport in tissues other than the kidney are distinct from Npt2 and, as such, would not contribute to the mutant phenotype.
We demonstrate that BBMs from Npt2−/− mice retain 20–30% of the Na+-Pi cotransport activity expressed in wild-type mice. Our data indicate that gene products other than Npt2 mediate Na+–Pi cotransport at the apical surface of the murine proximal nephron. Likely candidates for this activity are Npt1 (7) Ram-1 and Glvr-1 (34). Indeed, Npt1 expression was previously localized to the renal BBM of proximal tubular cells (35, 36). In addition, it has been shown that Ram-1 and Glvr-1, ubiquitous cell surface viral receptors that mediate high affinity, Na+-dependent Pi transport, are expressed in kidney (34). At present, little is known about the relative contribution of Npt1, Ram-1, and Glvr-1 to overall renal BBM Na+–Pi cotransport. However, our data in homozygous mutant mice suggest that Npt2 accounts for ≈70% of BBM Pi transport activity. Although these results are consistent with the relative distribution of Npt1, Npt2, Ram-1, and Glvr-1 mRNAs in normal mouse kidney (37), it is not clear whether Npt1-, Ram-1- or Glvr-1-mediated Na+-Pi cotransport is up-regulated in the absence of Npt2 activity.
Pi is an important determinant of 1,25(OH)2D synthesis in the kidney. Pi deprivation elicits an adaptive increase in the activity of the renal biosynthetic enzyme, 25-hydroxyvitamin D-1-hydroxylase (38, 39), which in turn leads to a corresponding increase in serum 1,25(OH)2D levels (40). In the present study, we demonstrate that hypophosphatemia, secondary to abrogation of renal Npt2 function, is also associated with a significant rise in the serum concentration of 1,25(OH)2D, thereby confirming the regulatory loop between extracellular Pi and renal vitamin D hormone synthesis. Previous studies have shown that the increase in 1,25(OH)2D elicits a marked stimulation in intestinal Pi (41) and calcium (42) absorption. Intestinal Pi hyperabsorption in Npt2 null mice would result in an increase in the filtered Pi load that, together with Npt2 ablation, is responsible for the substantial elevation in urinary Pi excretion. Intestinal calcium hyperabsorption in Npt2 null mice would lead to hypercalcemia, an increase in the filtered calcium load, and a suppression of PTH secretion, which contribute to the significant hypercalciuria observed in the homozygous mutant mice.
The phenotype of Npt2+/− mice is of considerable interest. Npt2+/− mice grow normally and are able to maintain normal serum Pi levels in the face of a modest increase in urinary Pi excretion. Moreover, the heterozygotes exhibit normal BBM Na+–Pi cotransport activity and an abundance of Npt2 protein that is comparable to that in wild-type mice in spite of a 50% reduction in Npt2 mRNA. These findings are likely the result of an adaptive response to the loss of one copy of the Npt2 gene. Previous studies have shown that renal BBM Na+–Pi cotransport and Npt2 cotransporter protein are both up-regulated by hypophosphatemia following low Pi challenge (14, 33). Although the renal Pi sensing mechanism that is involved in initiating the adaptive response to Pi deprivation has not yet been defined, our data suggest that kidneys of Npt2+/− mice are able to react appropriately to the increase in renal Pi loss and the resulting perturbation in Pi homeostasis.
Mice homozygous for the disrupted Npt2 gene have the biochemical features of patients with HHRH (43–47), yet the bone phenotype is markedly different in the human and mouse disorders. Children with HHRH present with radiological features of rickets, and adult patients with histomorphometric findings that are consistent with osteomalacia, such as irregular mineralization fronts, markedly elevated osteoid surface and seam width, increased number of osteoid lamellae, and prolonged mineralization time (48). In contrast, it does not appear from preliminary observations that the skeletal phenotype in Npt2−/− mice is similar to that in HHRH patients. There are several explanations for this discrepancy. (i) The bone response to hypophosphatemia and the Pi requirement for skeletal mineralization may differ substantially in humans and mice. Indeed, basal serum Pi levels are markedly different in the two species. (ii) Bone responses to elevated 1,25(OH)2D levels may differ in both species. The latter is suggested by a recent report showing differences in the regulation of human and murine osteocalcin gene expression by 1,25(OH)2D (49). (iii) A mutation in the NPT2 gene may not be the cause of HHRH.
The bone findings in mice homozygous for the disrupted Npt2 allele are clearly age dependent. With increasing age, Npt2−/− mice exhibit a dramatic reversal and eventual overcompensation of the skeletal changes apparent at 21 days of age. These differences may be attributed to age-related differences in the bone and intestinal response to 1,25(OH)2D. Recent studies in vitamin D receptor (VDR) null mice suggest that the phenotypic consequences of VDR ablation are not evident until after weaning, suggesting that 1,25(OH)2D may not play an important physiological role before 21 days of age (50, 51). Accordingly, osteoblast and osteoclast activity and intestinal Pi absorption may not be responsive to the elevated circulating levels of 1,25-(OH)2D in Npt2−/− mice before weaning, whereas after weaning, 1,25(OH)2D/VDR-dependent compensatory changes in intestinal Pi absorption and bone mineralization can occur. Further studies are necessary to determine whether this or other mechanisms contribute to the age-related differences in the bone phenotype of Npt2−/− mice.
We demonstrate that Npt2−/− mice have decreased circulating levels of PTH relative to wild-type littermates. Because PTH increases both osteoclast number and activity, reduced serum PTH levels in Npt2 null mice may contribute to compromised osteoclast function and a consequent bone remodeling defect. Preliminary data suggest that osteoclast number as well as tartrate-resistant acid phosphatase-positive and osteopontin-immunopositive cement lines are decreased in tibiae of 21-day Npt2−/− mice, relative to wild-type littermates, consistent with the notion that bone remodeling is impaired in young homozygous mutants.
In summary, we have demonstrated that mice homozygous for the disrupted Npt2 gene exhibit many of the features of HHRH and that the Npt2 gene plays an essential role in the regulation of Pi homeostasis and in normal skeletal development and growth. We believe that Npt2−/− mice provide a unique animal model to define the effects of disturbed Pi homeostasis not only on the skeleton but also on a variety of organ systems where Pi plays a crucial role and in disease states where aberrant Pi economy is manifest.
Acknowledgments
We thank Drs. H. Murer and J. Biber (University of Zurich) for the gift of the Npt2 antibody, Dr. P. Crine (University of Montreal) for the gift of the meprin mAb, and Hannah Hoag for critical review of the manuscript. This work was supported by grants from the Medical Research Council of Canada (Medical Research Council Group Grant in Medical Genetics to H.S.T. and Medical Research Council Grant to A.C.K.). L.B. was the recipient of Fellowship Awards from the McGill University-Montreal Children’s Hospital Research Institute and the Medical Research Council of Canada.
Footnotes
This paper was submitted directly (Track II) to the Proceedings Office.
Abbreviations: Pi, phosphate; BBM, brush-border membrane; PTH, parathyroid hormone; ES, embryonic stem cell; ALPase, alkaline phosphatase; 1,25(OH)2D, 1,25-dihydroxyvitamin D; FEI, fractional excretion index; HHRH, hereditary hypophosphatemic rickets with hypercalciuria; RT-PCR, reverse transcriptase–PCR.
References
- 1.Mizgala C L, Quamme G A. Physiol Rev. 1985;65:431–466. doi: 10.1152/physrev.1985.65.2.431. [DOI] [PubMed] [Google Scholar]
- 2.Murer H, Werner A, Reshkin S, Wuarin R, Biber J. Am J Physiol. 1991;260:C885–C899. doi: 10.1152/ajpcell.1991.260.5.C885. [DOI] [PubMed] [Google Scholar]
- 3.Berndt T J, Knox F G. In: The Kidney: Physiology and Pathophysiology. Seldin D W, Giebisch G, editors. New York: Raven; 1992. pp. 2511–2532. [Google Scholar]
- 4.Walker J J, Yan T S, Quamme G A. Am J Physiol. 1987;252:F226–F231. doi: 10.1152/ajprenal.1987.252.2.F226. [DOI] [PubMed] [Google Scholar]
- 5.Werner A, Moore M L, Mantei N, Biber J, Semenza G, Murer H. Proc Natl Acad Sci USA. 1991;88:9608–9612. doi: 10.1073/pnas.88.21.9608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Chong S S, Kristjansson K, Zoghbi H Y, Hughes M R. Genomics. 1993;18:355–359. doi: 10.1006/geno.1993.1476. [DOI] [PubMed] [Google Scholar]
- 7.Chong S S, Kozak C A, Liu L, Kristjansson K, Dunn S T, Bourdeau J E, Hughes M R. Am J Physiol. 1995;268:F1038–F1045. doi: 10.1152/ajprenal.1995.268.6.F1038. [DOI] [PubMed] [Google Scholar]
- 8.Magagnin S, Werner A, Markovich D, Sorribas V, Stange G, Biber J, Murer H. Proc Natl Acad Sci USA. 1993;90:5979–5983. doi: 10.1073/pnas.90.13.5979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sorribas V, Markovich D, Hayes G, Stange G, Forgo J, Biber J, Murer H. J Biol Chem. 1994;269:6615–6621. [PubMed] [Google Scholar]
- 10.Verri T, Markovich D, Perego C, Norbis F, Stange G, Sorribas V, Biber J, Murer H. Am J Physiol. 1995;268:F626–F633. doi: 10.1152/ajprenal.1995.268.4.F626. [DOI] [PubMed] [Google Scholar]
- 11.Collins J F, Ghishan F K. FASEB J. 1994;8:862–868. doi: 10.1096/fasebj.8.11.8070635. [DOI] [PubMed] [Google Scholar]
- 12.Hartmann C M, Wagner C A, Busch A E, Markovich D, Biber J, Lang F, Murer H. Pflügers Arch. 1995;430:830–836. doi: 10.1007/BF00386183. [DOI] [PubMed] [Google Scholar]
- 13.Helps C, Murer H, McGivan J. Eur J Biochem. 1995;228:927–930. doi: 10.1111/j.1432-1033.1995.tb20341.x. [DOI] [PubMed] [Google Scholar]
- 14.Levi M, Lotscher M, Sorribas V, Custer M, Arar M, Kaissling B, Murer H, Biber J. Am J Physiol. 1994;267:F900–F908. doi: 10.1152/ajprenal.1994.267.5.F900. [DOI] [PubMed] [Google Scholar]
- 15.Kempson S A, Lotscher M, Kaissling B, Biber J, Murer H, Levi M. Am J Physiol. 1995;268:F784–F791. doi: 10.1152/ajprenal.1995.268.4.F784. [DOI] [PubMed] [Google Scholar]
- 16.McKusick V A. Mendelian Inheritance in Man. Baltimore: Johns Hopkins Univ. Press; 1992. [Google Scholar]
- 17.Rasmussen H, Tenenhouse H S. In: The Molecular and Metabolic Basis of Inherited Diseases. Scriver C R, Beaudet A L, Sly W S, Valle D, editors. New York: McGraw-Hill; 1995. pp. 3717–3745. [Google Scholar]
- 18.Tenenhouse H S, Werner A, Biber J, Ma S, Martel J, Roy S, Murer H. J Clin Invest. 1994;93:671–676. doi: 10.1172/JCI117019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Beck L, Meyer R A, Jr, Meyer M H, Biber J, Murer H, Tenenhouse H S. Pflügers Arch. 1996;431:936–941. doi: 10.1007/s004240050088. [DOI] [PubMed] [Google Scholar]
- 20.Kos C H, Tihy F, Econs M J, Murer H, Lemieux N, Tenenhouse H S. Genomics. 1994;19:176–177. doi: 10.1006/geno.1994.1034. [DOI] [PubMed] [Google Scholar]
- 21.McPherson J D, Krane M C, Wagner-McPherson C B, Kos C H, Tenenhouse H S. Pediatr Res. 1997;41:632–634. doi: 10.1203/00006450-199705000-00005. [DOI] [PubMed] [Google Scholar]
- 22.Zhang X X, Tenenhouse H S, Hewson A S, Murer H, Eydoux P. Cytogenet Cell Genet. 1997;77:304–305. doi: 10.1159/000134603. [DOI] [PubMed] [Google Scholar]
- 23.Hartmann C M, Hewson A S, Kos C H, Hilfiker H, Soumoumou Y, Murer H, Tenenhouse H S. Proc Natl Acad Sci USA. 1996;93:7409–7414. doi: 10.1073/pnas.93.14.7409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Tybulewicz V L J, Crawford C E, Jackson P K, Bronson R T, Mulligan R C. Cell. 1991;65:1153–1163. doi: 10.1016/0092-8674(91)90011-m. [DOI] [PubMed] [Google Scholar]
- 25.Karaplis A C, Luz A, Glowacki J, Bronson R T, Tybulewicz V L J, Kronenberg H M, Mulligan R C. Genes Dev. 1994;8:277–289. doi: 10.1101/gad.8.3.277. [DOI] [PubMed] [Google Scholar]
- 26.Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Ed. Plainview, NY: Cold Spring Harbor Lab. Press; 1989. [Google Scholar]
- 27.Bradley A. In: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. Robertson E J, editor. Washington, DC: IRL; 1987. pp. 113–152. [Google Scholar]
- 28.Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer C, Tenenhouse H S. J Clin Invest. 1997;99:1200–1209. doi: 10.1172/JCI119276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Tenenhouse H S, Scriver C R. Can J Biochem. 1978;56:640–646. doi: 10.1139/o78-096. [DOI] [PubMed] [Google Scholar]
- 30.Laemmli U K. Nature (London) 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- 31.Corbeil D, Milhiet P, Simon V, Ingram J, Kenny A J, Boileau G, Crine P. FEBS Lett. 1993;335:361–366. doi: 10.1016/0014-5793(93)80420-y. [DOI] [PubMed] [Google Scholar]
- 32.Eicher E M, Southard J L, Scriver C R, Glorieux F H. Proc Natl Acad Sci USA. 1976;73:4667–4671. doi: 10.1073/pnas.73.12.4667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Tenenhouse H S, Martel J, Biber J, Murer H. Am J Physiol. 1995;268:F1062–F1069. doi: 10.1152/ajprenal.1995.268.6.F1062. [DOI] [PubMed] [Google Scholar]
- 34.Kavanaugh M P, Miller D G, Zhang W, Law W, Kozak S L, Kabat D, Miller A D. Proc Natl Acad Sci USA. 1994;91:7071–7075. doi: 10.1073/pnas.91.15.7071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Biber J, Custer M, Werner A, Kaissling B, Murer H. Pflügers Arch. 1993;424:210–215. doi: 10.1007/BF00384344. [DOI] [PubMed] [Google Scholar]
- 36.Custer M, Meier F, Schlatter E, Greger R, Garcia-Perez A, Biber J, Murer H. Pflügers Arch. 1993;424:203–209. doi: 10.1007/BF00384343. [DOI] [PubMed] [Google Scholar]
- 37.Tenenhouse H S, Roy S, Martel J. J Am Soc Nephrol. 1997;8:568A. (abstr.). [Google Scholar]
- 38.Baxter L A, DeLuca H F. J Biol Chem. 1976;251:3158–3161. [PubMed] [Google Scholar]
- 39.Gray R W, Napoli J L. J Biol Chem. 1983;258:1152–1155. [PubMed] [Google Scholar]
- 40.Tenenhouse H S, Jones G. J Clin Invest. 1990;85:1450–1455. doi: 10.1172/JCI114590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Cross H S, Debiec H, Peterlik M. Miner Electrolyte Metab. 1990;16:115–124. [PubMed] [Google Scholar]
- 42.van Os C H. Biochim Biophys Acta. 1987;906:195–222. doi: 10.1016/0304-4157(87)90012-8. [DOI] [PubMed] [Google Scholar]
- 43.Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Lieberman U A. N Engl J Med. 1985;312:611–617. doi: 10.1056/NEJM198503073121003. [DOI] [PubMed] [Google Scholar]
- 44.Tieder M, Modai D, Shaked U, Samuel R, Arie R, et al. N Engl J Med. 1987;316:125–129. doi: 10.1056/NEJM198701153160302. [DOI] [PubMed] [Google Scholar]
- 45.Proesmans W C, Fabrey G, Marchal G J, Gillis P L, Bouillon R. Pediatr Nephrol. 1987;1:479–484. doi: 10.1007/BF00849257. [DOI] [PubMed] [Google Scholar]
- 46.Chen C, Carpenter T, Steg N, Baron R, Anast C. Pediatrics. 1989;84:276–280. [PubMed] [Google Scholar]
- 47.Tieder M, Arie R, Bab I, Maor J, Liberman U A. Nephron. 1992;62:176–181. doi: 10.1159/000187029. [DOI] [PubMed] [Google Scholar]
- 48.Gazit D, Tieder M, Liberman U A, Passi-Even L, Bab I A. J Clin Endocrinol Metab. 1991;72:229–235. doi: 10.1210/jcem-72-1-229. [DOI] [PubMed] [Google Scholar]
- 49.Clemens T L, Tang H, Maeda S, Kesterson R A, Demayo F, Pike J W, Gundberg C M. J Bone Miner Res. 1997;12:1570–1576. doi: 10.1359/jbmr.1997.12.10.1570. [DOI] [PubMed] [Google Scholar]
- 50.Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, et al. Nat Genet. 1997;16:391–396. doi: 10.1038/ng0897-391. [DOI] [PubMed] [Google Scholar]
- 51.Li Y C, Pirro A E, Amling M, Delling G, Baron R, Bronson R, Demay M B. Proc Natl Acad Sci USA. 1997;94:9831–9835. doi: 10.1073/pnas.94.18.9831. [DOI] [PMC free article] [PubMed] [Google Scholar]